Chronic obstructive pulmonary disease market to hit $30.8b by 2033

Its growth is attributed to the introduction of new treatments.

The chronic obstructive pulmonary disease (COPD) market is projected to reach $30.8b by 2033 across the seven major markets, namely the US, France, Germany, Italy, Spain, the UK, and Japan, said GlobalData.

The expansion is attributed to the introduction of new treatments, including the first biologic for COPD, Sanofi and Regeneron’s Dupixent (dupilumab), and other therapies currently in development.

Meanwhile, inhaled corticosteroids, long-acting beta-2 agonists, and long-acting muscarinic antagonists will remain the dominant treatment modality for the disease.

 “The entry of these newer therapies will be used as add-on maintenance treatment for COPD patients, supplementing the SOC,” Asiyah Nawab, Pharma Analyst at GlobalData, said.

“While the COPD market is projected to grow strongly in the forecast period, potential barriers to this growth include loss of exclusivity within the forecast period,” Nawab added.